Targeson launches US contrast agent

Ultrasound imaging technology developer Targeson of La Jolla, CA, has introduced Visistar Integrin, a targeted ultrasound contrast agent for use in preclinical drug discovery and basic science research.

The microbubble contrast agent bears a covalently coupled peptide and is designed to selectively bind alphavbeta3 integrin on the vascular endothelial surface. Alphavbeta3 integrin is a biomarker of angiogenesis expressed on activated blood vessels.

Targeson said the contrast agent could be useful for investigating the cellular and molecular mechanisms of angiogenesis, molecular imaging of alphavbeta3 integrin expression, and evaluating anticancer therapies.

Related Reading

Targeson debuts US contrast agent, August 11, 2009

Copyright © 2009 AuntMinnie.com

Page 1 of 509
Next Page